Omnix Medical, an Israeli biopharmaceutical company working on new treatments for antibiotic-resistant infections, has raised $25 million in a Series C funding round. The round was co-led by Harel Insurance & Finance and the European Innovation Council (EIC) Fund.
Existing investors like Entrée Capital, Tal Ventures, Xenia Ventures, and Oriella Limited also participated, along with new investors such as Prevail Partners and OurCrowd.
With this new investment, Omnix Medical has now raised a total of $43 million since it was founded in 2015. Its main experimental treatment, OMN6, is being developed to fight some of the deadliest bacterial infections in the world.
The new funding will help Omnix complete Phase II trials for OMN6, targeting dangerous infections caused by Gram-negative bacteria, especially Acinetobacter baumannii, a hospital-acquired infection often resistant to strong antibiotics.
The new funds will also support regulatory preparations, manufacturing scale-up, and pipeline development of other engineered antimicrobial peptides, or AMPs, the company said.
Unlike regular antibiotics that attack specific bacterial functions, OMN6 works by directly destroying the bacterial cell membrane, allowing it to kill bacteria quickly, even if they are resistant to other drugs.
The compound has received Fast-Track and Qualified Infectious Disease Product (QIDP) status from the U.S. Food and Drug Administration.
Dr. Moshik Cohen-Kutner, CEO of Omnix Medical, said the new funding will allow the company to finish important clinical trials and improve its infrastructure.
“With the co-leadership of Harel Insurance & Finance and the EIC Fund, and the continued support of our existing shareholders, we now have the resources to complete our Phase II studies, strengthen our regulatory and manufacturing capabilities, and advance our entire pipeline,” he said.
Dr. Niv Bachnoff, Chief Scientific Officer added that OMN6’s selectivity rapid pore-forming action and engineered stability distinguish it from conventional antibiotics. “These qualities not only enable fast and effective treatment but also significantly minimize the likelihood of resistance development,” he said.
Read more- Coinbase to Increase Investment in CoinDCX, Valuing It at $2.45 Billion
